J. Driscoll

Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib

K. Anderson, E. Malek, T. Latif, 2015, Leukemia.

MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib

K. Anderson, S. Vallabhapurapu, N. Vad, 2014, Leukemia.

MiR-29 b replacement inhibits proteasomes and disrupts aggresome + autophagosome formation to enhance the antimyeloma bene fi t of bortezomib

K. Anderson, S. Vallabhapurapu, N. Vad, 2015 .

Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma

M. de Lima, T. Dosani, F. Covut, 2017, Blood Cancer Journal.

Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma

M van Duin, P. Sonneveld, A. Jegga, 2016, Leukemia.

Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods

E. Malek, J. Driscoll, M. Fernández-Ulloa, 2015, Blood Cancer Journal.